Medicure Inc (TSXV:MPH) is a pharmaceutical company focused on the development and commercialization of cardiovascular medicines for the U.S. market. Our vision is to become a leading pharmaceutical company within the U.S., offering a growing portfolio of products that improve patients' lives. We take pride in providing safe, efficacious, and cost-effective cardiovascular medicines that benefit both patients and healthcare providers.

Currently, we focus on the marketing & distribution of:
1. AGGRASTAT® (tirofiban hydrochloride) injections, a hospital-based product used in the cardiac catheterization lab. AGGRASTAT is the #1 used medication of its class in the U.S.
2. ZYPITAMAG® (pitavastatin) tablets, the latest statin medication approved by the FDA in 2017.

In 2020, we acquired Marley Drug, a local pharmacy in North Carolina. Our acquisition of Marley Drug increases patient access to medications, including Medicure's primary care drug, ZYPITAMAG® (Pitavastatin) tablets.

At Medicure, our passion drives us to innovate and find solutions to better support patients.

For more information, please see our website at www.medicure.com and follow us on Twitter at @MedicureInc. For guidelines on engaging with Medicure on social media, please visit bit.ly/MedicureSocial

Pharmaceutical

Medicure

Medicure's headquarters in Winnipeg, Canada

Albert D. Friesen

Neil Owens

Haaris Uddin

The Sales and Marketing team at Medicure is responsible for developing and executing strategies to promote the company's cardiovascular medicines, primarily AGGRASTAT® and ZYPITAMAG®, to healthcare providers and patients across the U.S. This team works on market analysis, advertising campaigns, and sales initiatives to drive product adoption and increase market share. They also manage relationships with hospitals, pharmacies, and healthcare professionals to ensure widespread distribution and access to Medicure's products.

Medicure

Org chart

Teams

Sales and Marketing

Offices

Medicure

Org chart

Teams

Sales and Marketing

Offices

Related companies